Ducroix J-P, Outurquin S, Benabes-Jezraoui B, Gras V, Chaby G, Strunski V, Salle V, Smail A, Lok C, Andrejak M
Service de médecine interne, CHU Amiens Nord, place Victor-Pauchet, 80054 Amiens cedex 1, France.
Rev Med Interne. 2004 Jul;25(7):501-6. doi: 10.1016/j.revmed.2004.02.024.
Inhibitors of angiotensin-converting enzyme are worldwide used and are a real progress for the treatment of systemic hypertension or cardiac failure and are a real progress. The most common adverse side effect is cough. Angioedema is a sudden and localized edema involving the deeper cutaneous and mucosa tissue lappers. 0.1-0.5% of patients treated by ACE inhibitors could develop angioedema.
We report a series of 19 cases, recruited in the Parmacovigilance Center of the University Hospital of Amiens from 1997 to 2003.
All the patients had a facial swelling edema at initial presentation. Intestinal mucosa or preputial are misleading localisations. In 1/3 of cases, angioedema appeared after the first administration, in 1/3 of cases it appeared with a delay of 1-2 years. The oropharynx localisation with glottic involvement may need an airway intervention. One patient died from pulmonary distress at home.
The pathophysiology is current unknown although there is increasing evidence for bradykinin accumulation involvement. The treatment by ACE inhibitors must be broken off; angiotensin II antagonists may be an alternative treatment, but has to be introduced carefully.
血管紧张素转换酶抑制剂在全球范围内广泛应用,是治疗系统性高血压或心力衰竭的一项重大进展。最常见的不良反应是咳嗽。血管性水肿是一种突发的局限性水肿,累及更深层的皮肤和黏膜组织层。接受血管紧张素转换酶抑制剂治疗的患者中有0.1% - 0.5%可能发生血管性水肿。
我们报告了1997年至2003年在亚眠大学医院药物警戒中心招募的一系列19例病例。
所有患者初诊时均有面部肿胀性水肿。肠道黏膜或包皮部位是具有误导性的发病部位。在1/3的病例中,血管性水肿在首次用药后出现,1/3的病例在用药1 - 2年后出现。累及声门的口咽部发病部位可能需要气道干预。1例患者在家中死于肺窘迫。
尽管越来越多的证据表明缓激肽蓄积参与其中,但目前其病理生理学尚不清楚。必须停用血管紧张素转换酶抑制剂治疗;血管紧张素II拮抗剂可能是一种替代治疗方法,但必须谨慎使用。